ArticleJournal of clinical immunology2024

Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study.

Arye Rubinstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.